![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 1
Zeitschriftenartikel
Boukovala, Myrto; Modest, Dominik Paul; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Peveling Genannt Reddemann, C.; Graeven, Ullrich 
ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]
ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]